Supporting strategic fundamental research in life sciences through carefully selected projects from universities in the Wallonia-Brussels Federation, with a view to transforming their discoveries into industrial applications.
WELBIO lance aujourd’hui une plateforme digitale permettant aux citoyens de se déclarer volontaires pour des études cliniques relatives au Covid-19 : https://rechercheclinique.be/
These results from the team of Jean-Luc Balligand (WELBIO – IREC - UCLouvain) pave the way for the development of more potent molecules to block aquaporin and treat heart failure more efficiently.
This jammer prevents proper regulation of sugar, causing insulin resistance in people with diabetes. Patrice Cani (UCLouvain) and Claude Knauf (INSERM) also discover that a lipid produced by our body helps preventing this dysfunction.
WELBIO's essential mission is to support top level fundamental research in life sciences. This mission is currently integrated with the Fonds de la Recherche Fondamentale Stratégique (F.R.S.-FNRS).
WELBIO supports fundamental research with the view to translate scientific results into industrial applications. Through valorisation committees, a sustained focus is kept on the protection of intellectual property in particular.
The WELBIO Bridge Fund is a research funding instrument intended for WELBIO investigators and designed to bridge the gap between early stage research and the development of a competitive package for the next funding step
With its focus on life sciences, WELBIO holds a unique position between fundamental research in all fields and applied biomedical research sur les sciences du vivant. WELBIO works closely with the FRNS and BioWin in particular.
